Every material Form 8-K Crown Reserve Acquisition Corp. I has filed with the SEC since April 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Crown Reserve Acquisition Corp. I (CRAC) and Carvix, Inc. signed a second amendment to their business combination agreement on September 23, 2026. The amendment moves the deadline after which either party may terminate the deal to the later of February 10, 2027 or the date required under the company's organizational documents, up from September 30, 2026. Shareholders should note that the deal timeline has been extended, and the transaction remains subject to shareholder approval and other closing conditions.
Second Amendment to Business Combination Agreement signed September 23, 2026, following a First Amendment dated August 26, 2026.
Outside Date extended to the later of February 10, 2027 and the date required under the company's pre-domestication organizational documents; previously September 30, 2026.
Except as amended, the original business combination agreement dated March 30, 2026 remains in effect.
On August 26, 2026, Crown Reserve Acquisition Corp. I (CRAC), its merger subsidiary and Carvix, Inc. signed a First Amendment to their March 30, 2026 Business Combination Agreement. The amendment restates the shareholder vote thresholds for the extraordinary general meeting, makes the advisory organizational documents proposal non-binding and not a closing condition, and sets minimum annualized base salaries for named Carvix executives. The filing states that the amendment does not change any holder's voting rights, and it does not disclose financial results or a deal value.
Amendment dated August 26, 2026 amends the Business Combination Agreement dated March 30, 2026.
Domestication and organizational documents proposals require a special resolution of at least two-thirds of Class B ordinary shares; Class A holders have no vote on them.
Advisory organizational documents proposals are non-binding and are not a condition to completing the transaction.
Base salaries for Carvix executives are set at minimums listed in Annex A, which the filing does not reproduce in its text.
On March 30, 2026, Crown Reserve Acquisition Corp. I (CRAC) signed a Business Combination Agreement with Carvix, Inc., a Delaware corporation, under which Carvix would merge into a subsidiary of the SPAC and survive as a wholly owned subsidiary. Carvix stockholders would receive 50,000,001 SPAC common shares at closing, plus up to 50,000,100 earnout shares over four years, which would dilute existing SPAC shareholders.
Agreement signed March 30, 2026, with Carvix, Inc.; the SPAC would first domesticate to Delaware.
Carvix stockholders to receive 50,000,001 shares at the Effective Time, plus up to 50,000,100 earnout shares.
Earnout split equally between EBITDA targets (first year $10.38 million) and revenue targets (first year $276.8 million), with payment years starting January 1, 2027.
Either party may terminate if closing has not occurred by September 30, 2026, the Outside Date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Crown Reserve Acquisition Corp. I filing is on SEC EDGAR ↗. 8-K briefs of other companies →